High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
CRISPR-Cas9 nucleases are widely used for genome editing but can induce unwanted off-target mutations. Existing strategies for reducing genome-wide off-target effects of the widely used Streptococcus pyogenes Cas9 (SpCas9) are imperfect, possessing only partial or unproven efficacies and other limitations that constrain their use. Here we describe SpCas9-HF1, a high-fidelity variant harbouring alterations designed to reduce non-specific DNA contacts. SpCas9-HF1 retains on-target activities comparable to wild-type SpCas9 with >85% of single-guide RNAs (sgRNAs) tested in human cells. Notably, with sgRNAs targeted to standard non-repetitive sequences, SpCas9-HF1 rendered all or nearly all off-target events undetectable by genome-wide break capture and targeted sequencing methods. Even for atypical, repetitive target sites, the vast majority of off-target mutations induced by wild-type SpCas9 were not detected with SpCas9-HF1. With its exceptional precision, SpCas9-HF1 provides an alternative to wild-type SpCas9 for research and therapeutic applications. More broadly, our results suggest a general strategy for optimizing genome-wide specificities of other CRISPR-RNA-guided nucleases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Precision editing of alleles in a human cell has drastically improved the understanding of genotypic and phenotypic effects in gene therapy due to the lower off-target rates [119,120,121].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To address off-target issues, using the CRISPR system in the form of a rRNP and utilizing high-fidelity CRISPR variants can help minimize off-target effects (Kleinstiver et al., 2016).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Kleinstiver et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kleinstiver et al. developed the high-fidelity SpCas9-HF1, a variant that produced undetectable genome-wide off-target cleavage [134].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [134]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, a series of optimized mutations in SpCas9 have greatly improved the editing specificity of Cas9 variants without substantially attenuating the editing activity.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“Some active gRNAs for SpCas9-WT showed very low editing ability in SpCas9 variants.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, S., Cooper, A., Markowitz, S., Duran, C., et al. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts199 · Cited by 20,027
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citation
Cited by
Items 901–1,000 of 1,017
Precise and broad scope genome editing based on high-specificity Cas9 nickases
Wang, Q., Liu, J., Janssen, J. M., Le Bouteiller, M., Frock, R. L., & Gonçalves, M. A. F. V. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1236 · Cited by 41
“1) (23), Sniper-Cas9 (24), SpCas9-HF1 (25), evoCas9 (26) and xCas9-3.”
Mahato, R. K., Bhattacharya, S., Khullar, N., Sidhu, I. S., Reddy, P. H., Bhatti, G. K., & Bhatti, J. S. (2023) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2023.12.003 · Cited by 44
Yang, P., Lou, Y., Geng, Z., Guo, Z., Wu, S., Li, Y., Song, K., Shi, T., Zhang, S., Xiong, J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067890 · Cited by 41
Evolution-guided protein design of IscB for persistent epigenome editing in vivo
Kannan, S., Altae-Tran, H., Zhu, S., Xu, P., Strebinger, D., Oshiro, R., Faure, G., Moeller, L., Pham, J., Mears, K. S., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02655-3 · Cited by 48
“…the initial deployment of Streptococcus pyogenes CRISPR–Cas9 (SpCas9) for mammalian genome editing, genome mining 2–7 , rational mutagenesis and structure-guided protein design 8,9 , and directed evolution approaches 10,11 have resulted in new systems with improved activity, specificity and size.”
Diving into marine genomics with CRISPR/Cas9 systems
Momose, T., & Concordet, J. (2016) · Marine Genomics · doi:10.1016/j.margen.2016.10.003 · Cited by 44
Rutkowski, T. P., Schroeder, J. P., Gafford, G. M., Warren, S. T., Weinshenker, D., Caspary, T., & Mullé, J. G. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23970 · Cited by 43
Abdallah, Q. A., Souza, A. C. O., Martín‐Vicente, A., Ge, W., & Fortwendel, J. R. (2018) · Fungal Biology and Biotechnology · doi:10.1186/s40694-018-0057-2 · Cited by 41
Synergizing CRISPR/Cas9 off-target predictions for ensemble insights and practical applications
Zhang, S., Li, X., Lin, Q., & Wong, K. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty748 · Cited by 43
Therapeutic gene editing in haematological disorders with CRISPR /Cas9
Jensen, T. I., Axelgaard, E., & Bak, R. O. (2019) · British Journal of Haematology · doi:10.1111/bjh.15851 · Cited by 43
“Several high-fidelity SpCas9 nuclease variants have been engineered to decrease non-specific interactions with the DNA target site (Kleinstiver et al, 2016; Slaymaker et al, 2016).”
BackgroundA short overview of CRISPR-Cas technology and its application in viral disease control
Ghorbani, A., Hadifar, S., Salari, R., Izadpanah, K., Burmistrz, M., Afsharifar, A., Eskandari, M. H., Niazi, A., Denes, C. E., & Neely, G. G. (2021) · Transgenic Research · doi:10.1007/s11248-021-00247-w · Cited by 36
“In addition, several enhanced fidelity variants of SpCas9 such as eSpCas9 (1.1), SpCas9-HF1, and HeFSpCas9 were produced by rational design to increase on-target editing activity and improve intrinsic SpCas9 specificity (Chen et al. 2017; Kleinstiver et al. 2016; Kulcsár et al. 2017).”
BackgroundInfluentialOura, S., Noda, T., Morimura, N., Hitoshi, S., Nishimasu, H., Nagai, Y., Nureki, O., & Ikawa, M. (2021) · Communications Biology · doi:10.1038/s42003-021-02304-w · Cited by 42
Strategies for High-Efficiency Mutation Using the CRISPR/Cas System
Feng, S., Wang, Z., Li, A., Xie, X., Liu, J., Li, S., Li, Y., Wang, B., Hu, L., Yang, L., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.803252 · Cited by 46
“So far, several highly specific Cas9 variants have been identified, including eSpCas9 (Slaymaker et al., 2016), SpCas9-HF1 (Kleinstiver et al., 2016), HypaCas9 (Chen et al., 2017), xCas9 (Legut et al., 2020), Sniper-Cas9 (Lee et al., 2018), evo Cas9 (evolved Cas9) (Casini et al., 2018), HiFiCas9 (Vakulskas et al., 201…”
BackgroundInfluentialPrecision targeting tumor cells using cancer-specific InDel mutations with CRISPR-Cas9
Kwon, T., Ra, J. S., Lee, S., Baek, I., Khim, K. W., Lee, E. A., Song, E. K., Otarbayev, D., Jung, W., Park, Y. H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103532119 · Cited by 41
Eslami-Mossallam, B., Klein, M., van der Smagt, C. P., van der Sanden, K., Jones, S. K., Hawkins, J. A., Finkelstein, I. J., & Depken, M. (2022) · Nature Communications · doi:10.1038/s41467-022-28994-2 · Cited by 44
Epigenetic marks for mitigating abiotic stresses in plants
Ali, S., Khan, N., & Tang, Y. (2022) · Journal of Plant Physiology · doi:10.1016/j.jplph.2022.153740 · Cited by 41
Das, T., Anand, U., Pal, T., Mandal, S., Kumar, M., CHAUHAN, R., Gopalakrishnan, A. V., de la Lastra, J. M. P., & Dey, A. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28344 · Cited by 45
A most formidable arsenal: genetic technologies for building a better mouse
Clark, J. F., Dinsmore, C. J., & Soriano, P. M. (2020) · Genes & Development · doi:10.1101/gad.342089.120 · Cited by 46
“Directed mutagenesis has producedmultiple high-fidelity enzymes that boast on-target activity comparable with wild type with significantly reduced levels of off-target mutations (Kleinstiver et al. 2016; Slaymaker et al. 2016; Chen et al. 2017; Lee et al. 2018).”
BackgroundLi, J., Wu, S., Zhang, K., Sun, X., Lin, W., Wang, C., & Lin, S. (2024) · Microorganisms · doi:10.3390/microorganisms12010118 · Cited by 45
“To suppress the off-target activity, researchers have developed a series of Cas9 mutants (e.g., Cas9-HF1, eCas9, HypaCas9, nCas9, and fCas9) with modifications in the spatial structure or active site, which result in a significant reduction in off-target rate [25–29].”
BackgroundCRISPR-M: Predicting sgRNA off-target effect using a multi-view deep learning network
Sun, J., Guo, J. H., & Liu, J. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011972 · Cited by 41
New and emerging uses of CRISPR/Cas9 to genetically manipulate apicomplexan parasites
Cristina, M. D., & Carruthers, V. B. (2018) · Parasitology · doi:10.1017/s003118201800001x · Cited by 45
Recent advances in CRISPR/Cas9 mediated genome editing in Bacillus subtilis
Hong, K., Liu, D., Chen, T., & Wang, Z. (2018) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-018-2537-1 · Cited by 41
CRISPR babies: when will the world be ready?
Ledford, H. K. (2019) · Nature · doi:10.1038/d41586-019-01906-z · Cited by 39
Lee, B., Lozano, R. J., & Dunbar, C. E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.001 · Cited by 42
mRNA-mediated delivery of gene editing tools to human primary muscle stem cells
Stadelmann, C., Francescantonio, S. D., Marg, A., Müthel, S., Spuler, S., & Escobar, H. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.02.016 · Cited by 43
Genome-editing technologies for gene correction of hemophilia
Park, C., Lee, D. R., Sung, J. J., & Kim, D. (2016) · Human Genetics · doi:10.1007/s00439-016-1699-x · Cited by 45
Murray, A., Gough, G., Cindrić, A., Vučković, F., Koschut, D., Borelli, V., Petrović, D. J., Bekavac, A., Plećaš, A., Hribljan, V., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104692 · Cited by 48
A versatile CRISPR/Cas9 system off-target prediction tool using language model
Du, W., Zhao, L., Diao, K., Zheng, Y., Yang, Q., Zhu, Z., Zhu, X., & Tang, D. (2025) · Communications Biology · doi:10.1038/s42003-025-08275-6 · Cited by 43
Karimi, M. A., Paryan, M., Fard, G. B., Sadeghian, H., Zarrinfar, H., & Bafghi, M. H. (2025) · Medical Principles and Practice · doi:10.1159/000547334 · Cited by 55
Kantor, B., O’Donovan, B., & Chiba‐Falek, O. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102635 · Cited by 40
In vivo disruption of latent HSV by designer endonuclease therapy
Aubert, M., Madden, E. A., Loprieno, M. A., Feelixge, H. S. D. S., Stensland, L., Huang, M.-L. W., Greninger, A. L., Roychoudhury, P., Niyonzima, N., Nguyen, T., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88468 · Cited by 41
“In addition, optimization of single guide RNA (sgRNA) length (47) and the development of high-fidelity Cas9 variants (48, 49) now provide the CRISPR/”
BackgroundPossible interventions to modify aging
Libertini, G., & Ferrara, N. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916120038 · Cited by 39
Use of CRISPR/Cas9 for Symbiotic Nitrogen Fixation Research in Legumes
Wang, L., Wang, L., Zhou, Y., & Duanmu, D. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.03.010 · Cited by 45
Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1
Yang, M., Wei, H., Wang, Y., Deng, J., Tang, Y., Zhou, L., Guo, G. F., & Tong, A. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.05.009 · Cited by 43
Multiplex CRISPR/Cas9 system impairs HCMV replication by excising an essential viral gene
Gergen, J., Coulon, F., Crénéguy, A., Elain-Duret, N., Gutiérrez-Guerrero, A., Pinkenburg, O., Verhoeyen, E., Anegón, I., Nguyen, T. H., Halary, F. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192602 · Cited by 38
Sanjurjo-Soriano, C., & Kalatzis, V. (2018) · Neural Plasticity · doi:10.1155/2018/5056279 · Cited by 43
Progress and challenges in development of new therapies for urea cycle disorders
Soria, L. R., Mew, N. A., & Brunetti‐Pierri, N. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz140 · Cited by 39
Gene therapy and genome editing for primary immunodeficiency diseases
Zhang, Z., Thrasher, A. J., & Zhang, F. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.07.007 · Cited by 40
A Tale of Two Moieties: Rapidly Evolving CRISPR/Cas-Based Genome Editing
Yang, L. C., & Chen, J. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.06.003 · Cited by 40
“, eSpCas9 [125], SpCas9-HF [126], HypaCas9 [127], and Sniper-Cas9 [128]) could reduce their binding at OT sites, but their binding and editing ability at ON sites largely remain.”
BackgroundInfluentialGuide-target mismatch effects on dCas9–sgRNA binding activity in living bacterial cells
Feng, H., Guo, J., Wang, T., Zhang, C., & Xing, X. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1295 · Cited by 39
“ing that attenuating the interactions between Cas9 and nucleic acids, which results in less energy compensation during strand invasion, could improve the specificity (25,43,44).”
BackgroundMusunuru, K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.002 · Cited by 44
crisprSQL: a novel database platform for CRISPR/Cas off-target cleavage assays
Störtz, F., & Minary, P. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa885 · Cited by 37
“(18) Guide-seq DSBs 7 61 28 hg19 U2OS (19) BLESS DSBs 3 31 31 HEK (20) CIRCLE-seq DSBs 18 7374 3493 hg19 HEK293, U2OS, K562 (21) Guide-seq DSBs 5 203 107 hg19 U2OS”
BackgroundOptimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9
Amiri, M., Moaveni, A. K., Zolbin, M. M., Shademan, B., & Nourazarian, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1462697 · Cited by 42
The expanding footprint of CRISPR/Cas9 in the plant sciences
Schaeffer, S. M., & Nakata, P. A. (2016) · Plant Cell Reports · doi:10.1007/s00299-016-1987-x · Cited by 40
Efficient Production of Gene-Modified Mice using Staphylococcus aureus Cas9
Zhang, X., Liang, P., Ding, C., Zhang, Z., Zhou, J., Xie, X., Huang, R., Sun, Y., Sun, H., Zhang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep32565 · Cited by 39
Current status of genome editing in vector mosquitoes: A review
Reegan, A. D., Ceasar, S. A., Paulraj, M. G., Savarimuthu Ignacimuthu, S. J., & Al-Dhabi, N. A. (2016) · BioScience Trends · doi:10.5582/bst.2016.01180 · Cited by 44
Safety, Security, and Policy Considerations for Plant Genome Editing
Wolt, J. D. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.03.005 · Cited by 44
CRISPR‐Enabled Tools for Engineering Microbial Genomes and Phenotypes
Tarasava, K., Oh, E. J., Eckert, C. A., & Gill, R. T. (2018) · Biotechnology Journal · doi:10.1002/biot.201700586 · Cited by 38
The technical risks of human gene editing
Davies, B. (2019) · Human Reproduction · doi:10.1093/humrep/dez162 · Cited by 39
“The developed Cas enzymes and orthologues with reported higher accuracy may be very useful in this context (Kim et al., 2016; Kleinstiver et al., 2016; Slaymaker et al., 2016; Teng et al., 2018).”
BackgroundApplication of CRISPR genetic screens to investigate neurological diseases
So, R. W. L., Chung, S., Lau, H. H. C., Watts, J. J., Gaudette, E. V., Al‐Azzawi, Z. A. M., Bishay, J., Lin, L. T., Joung, J., Wang, X., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0343-3 · Cited by 40
Self-citationEditor's cut: DNA cleavage by CRISPR RNA-guided nucleases Cas9 and Cas12a
Swartjes, T., Staals, R. H. J., & John van der, O. O. S. T. (2019) · Biochemical Society Transactions · doi:10.1042/bst20190563 · Cited by 39
Rapid and precise genome editing in a marine diatom, Thalassiosira pseudonana by Cas9 nickase (D10A)
Nawaly, H., Tsuji, Y., & Matsuda, Y. (2020) · Algal Research · doi:10.1016/j.algal.2020.101855 · Cited by 40
On-Target CRISPR/Cas9 Activity Can Cause Undesigned Large Deletion in Mouse Zygotes
Korablev, A. N., Lukyanchikova, V., Serova, I. A., & Баттулин, Н. Р. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103604 · Cited by 40
“Furthermore, numerous molecular biology strategies were described to significantly reduce off-target genome activities: alternative editing enzymes, such as dimeric fusions with FokI [26,27], CpfI [28,29], small Cas9 orthologs [30], CasX [31], and modified spCas9 enzymes [32,33]; improved delivery strategies, such as…”
BackgroundHigh-fidelity detection of DNA combining the CRISPR/Cas9 system and hairpin probe
Wang, M., Han, D., Zhang, J., Zhang, R., & Li, J. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113212 · Cited by 38
CRISPR screen in cancer: status quo and future perspectives.
He, C., Han, S., Chang, Y., Wu, M., Zhao, Y., Chen, C. Y., & Chu, X. (2021) · American Journal of Cancer Research · Cited by 49
CRISPR-targetedMAGT1insertion restores XMEN patient hematopoietic stem cells and lymphocytes
Brault, J., Liu, T., Bello, E. A., Liu, S., Sweeney, C. L., Meis, R. J., Koontz, S. M., Corsino, C. I., Choi, U., Vayssière, G., et al. (2021) · Blood · doi:10.1182/blood.2021011192 · Cited by 38
Self-citationCRISPR/Cas genome editing in grapevine: recent advances, challenges and future prospects
Ren, C., Lin, Y., & Liang, Z. (2022) · Fruit Research · doi:10.48130/frures-2022-0007 · Cited by 40
Engineered M2a macrophages for the treatment of osteoarthritis
Liang, C., Wu, S. J., Xia, G., Huang, J., Wen, Z., Zhang, W., & Cao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1054938 · Cited by 37
Progresses, Challenges, and Prospects of CRISPR/Cas9 Gene-Editing in Glioma Studies
Kang, X., Wang, Y., Liu, P., Huang, B., Zhou, B., Lu, S., Geng, W., & Tang, H. (2023) · Cancers · doi:10.3390/cancers15020396 · Cited by 39
Systematically attenuating DNA targeting enables CRISPR-driven editing in bacteria
Collias, D., Vialetto, E., Yu, J., Co, K., Almási, É. D. H., Rüttiger, A.-S., Achmedov, T., Strowig, T., & Beisel, C. L. (2023) · Nature Communications · doi:10.1038/s41467-023-36283-9 · Cited by 39
Using Xenopus to understand human disease and developmental disorders
Sater, A. K., & Moody, S. A. (2017) · genesis · doi:10.1002/dvg.22997 · Cited by 43
Applications of Alternative Nucleases in the Age of CRISPR/Cas9
Guha, T. K., & Edgell, D. R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122565 · Cited by 43
CRISPR–Cas9 Genetic Analysis of Virus–Host Interactions
Gebre, M. S., Nomburg, J., & Gewurz, B. E. (2018) · Viruses · doi:10.3390/v10020055 · Cited by 42
Crystal structure of xCas9 in complex with sgRNA and target DNA (AAG PAM): 6aeb
Guo, M., Ren, K., Zhu, Y., & Huang, Z. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6aeb/pdb · Cited by 36
Toward Combined Cell and Gene Therapy for Genodermatoses
Rosa, L. D., Latella, M. C., Seconetti, A. S., Cattelani, C., Bauer, J. W., Bondanza, S., & Luca, M. D. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a035667 · Cited by 38
Rahimi, A., Esmaeili, Y., Dana, N., Dabiri, A., Rahimmanesh, I., Jandaghian, S., Vaseghi, G., Shariati, L., Zarrabi, A., Javanmard, S. H., et al. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106476 · Cited by 38
Xu, K., Feng, H., Zhang, H., He, C., Kang, H., Yuan, T., Shi, L., Zhou, C., Hua, G., Cao, Y., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01220-8 · Cited by 37
Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform
Fang, Y., Chen, Y., & Li, Y.-R. (2025) · Stem Cell Reports · doi:10.1016/j.stemcr.2025.102515 · Cited by 40
Mini-review on current strategies to knockdown long non-coding RNAs
Behlke, M. A. (2016) · Journal of Rare Diseases Research & Treatment · doi:10.29245/2572-9411/2016/3.1066 · Cited by 39
Mouse medulloblastoma driven by CRISPR activation of cellular Myc
Vo, B. T., Kwon, J. A., Li, C., Finkelstein, D., Xu, B., Orr, B. A., Sherr, C. J., & Roussel, M. F. (2018) · Scientific Reports · doi:10.1038/s41598-018-24956-1 · Cited by 39
Protein Engineering Strategies to Expand CRISPR-Cas9 Applications
Ribeiro, L. F., Ribeiro, L. F. C., Barreto, M. Q., & Ward, R. J. (2018) · International Journal of Genomics · doi:10.1155/2018/1652567 · Cited by 40
DNA, RNA, and Protein Tools for Editing the Genetic Information in Human Cells
Chen, X., & Gonçalves, M. A. F. V. (2018) · iScience · doi:10.1016/j.isci.2018.08.001 · Cited by 37
Yuan, T., Zhong, Y., Wang, Y., Zhang, T., Lü, R., Zhou, M., Lu, Y., Yan, K., Chen, Y., Hu, Z., et al. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1013-8 · Cited by 37
Li, B., Ren, N., Yang, L., Liu, J., & Huang, Q. (2019) · Scientific Reports · doi:10.1038/s41598-019-55463-6 · Cited by 38
Genome Editing for CNS Disorders
Duarte, F. T., & Déglon, N. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.579062 · Cited by 36
Delivery Platforms for CRISPR/Cas9 Genome Editing of Glial Cells in the Central Nervous System
Meneghini, V., Peviani, M., Luciani, M., Zambonini, G., & Gritti, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.644319 · Cited by 41
“Additionally, the use of high-fidelity Cas9 proteins engineered to decrease non-specific DNA interactions through the modification of DNA-binding domains could strongly contribute to increase target specificity and minimize Cas9 promiscuity (Kleinstiver et al., 2016; Rees et al., 2017; Vakulskas et al., 2018; Wang et…”
BackgroundSharma, A. K., Nymark, M., Flo, S., Sparstad, T., Bones, A. M., & Winge, P. (2021) · Plant Biotechnology Journal · doi:10.1111/pbi.13582 · Cited by 37
“A HiFi Cas9 variant (SpCas9-HF1) (Kleinstiver et al., 2016) and enhanced specificity SpCas9 (eSpCas9) (Slaymaker et al., 2016) variants were created by substituting four amino acids.”
BackgroundMethodResultInfluentialUsing CRISPR to understand and manipulate gene regulation
Akıncı, E., Hamilton, M. C., Khowpinitchai, B., & Sherwood, R. I. (2021) · Development · doi:10.1242/dev.182667 · Cited by 37
Pathological Bases and Clinical Application of Long Noncoding RNAs in Cardiovascular Diseases
Zhang, C., Niu, K., Lian, P., Hu, Y., Shuai, Z., Gao, S., Ge, S., Xu, T., Xiao, Q., & Chen, Z. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16752 · Cited by 36
The application of genome editing technology in fish
Lü, J., Fang, W., Huang, J., & Li, S. (2021) · Marine Life Science & Technology · doi:10.1007/s42995-021-00091-1 · Cited by 37
Yin, H., Zhou, B., Dong, C., Zhang, Y., Yu, J., Pu, Y., Feng, W., Sun, L., Hu, H., Chen, Y., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202107093 · Cited by 37
Challenges for the Applications of Human Pluripotent Stem Cell-Derived Liver Organoids
Chang, M., Bogacheva, M. S., & Lou, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.748576 · Cited by 37
CRISPR and cardiovascular diseases
Musunuru, K. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac048 · Cited by 38
CRISPR-Cas system: from diagnostic tool to potential antiviral treatment
Rajan, A., Shrivastava, S., Janhawi, Kumar, A., Singh, A. K., & Arora, P. K. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-12135-2 · Cited by 37
Rescue of hearing by adenine base editing in a humanized mouse model of Usher syndrome type 1F
Peters, C. W., Hanlon, K. S., Ivanchenko, M. V., Zinn, E. M., Linarte, E., Li, Y., Levy, J. M., Liu, D. R., Kleinstiver, B. P., Indzhykulian, A. A., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.007 · Cited by 36
Self-citationLu, X., Zhang, M., Li, G., Zhang, S., Zhang, J., Fu, X., & Sun, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713202 · Cited by 45
“It is essential to acknowledge that the TwinPE system necessitates artificially introducing integral sub-quality [9].”
BackgroundAli, J. H., & Walter, M. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03041-2 · Cited by 39
“…conventional and Crisp/Cas9 induced alternative splicing [88, 89, 132], alternative splicing with splice-switching oligonucleotides [133, 134–137, 206, 208], the use of phytochemicals with a wide variety of different targets [257]; Crisp/ Cas9 based and other telomere deprotection measures [183,…”
BackgroundEmerging Gene Therapeutics for Epidermolysis Bullosa under Development
Bischof, J., Hierl, M., & Koller, U. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042243 · Cited by 39
Use of genome-editing tools to treat sickle cell disease
Tasan, I., Jain, S., & Zhao, H. (2016) · Human Genetics · doi:10.1007/s00439-016-1688-0 · Cited by 37
“Two recently engineered Cas9 variants eSpCas9 and SpCas9-HF1 were also highly successful at improving specificity (Slaymaker et al. 2016; Kleinstiver et al. 2016).”
Functional interrogation of non-coding DNA through CRISPR genome editing
Canver, M. C., Bauer, D. E., & Orkin, S. H. (2017) · Methods · doi:10.1016/j.ymeth.2017.03.008 · Cited by 39
Impact of Genetic Variation on CRISPR-Cas Targeting
Canver, M. C., Joung, J. K., & Pinello, L. (2018) · The CRISPR Journal · doi:10.1089/crispr.2017.0016 · Cited by 37
Self-citationCRISPR/Cas9‐Based Genome Editing and its Applications for Functional Genomic Analyses in Plants
Li, J., Li, Y., & Ma, L. (2019) · Small Methods · doi:10.1002/smtd.201800473 · Cited by 37
Deep sampling of gRNA in the human genome and deep-learning-informed prediction of gRNA activities
Zhang, H., Yan, J., Lu, Z., Zhou, Y., Zhang, Q., Cui, T., Li, Y., Chen, H., & Ma, L. (2023) · Cell Discovery · doi:10.1038/s41421-023-00549-9 · Cited by 36
CRISPR/Cas-Mediated Genome Engineering in Plants: Application and Prospectives
Mishra, S., Nayak, S., Tuteja, N., Poosapati, S., Swain, D. M., & Sahoo, R. K. (2024) · Plants · doi:10.3390/plants13141884 · Cited by 39
Harnessing the evolving CRISPR/Cas9 for precision oncology
Li, T., Li, S., Kang, Y., Zhou, J., & Yi, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05570-4 · Cited by 40
“Similar to traditional CRISPR editing technology, replacing with high-fidelity Cas9 variants [70, 122] can decrease Cas protein-dependent off-target, and change or evolve to higher activity and targeting specific deaminase [123–130] can reduce the Cas-inde-pendent off-target.”
BackgroundMethodEmerging Approaches for Spatiotemporal Control of Targeted Genome with Inducible CRISPR-Cas9
Nihongaki, Y., Otabe, T., & Sato, M. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04757 · Cited by 39
Chen, D., Xu, T., Tu, M., Xu, J., Zhou, C., Cheng, L., Yang, R., Yang, T., Zheng, W., He, X., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00453 · Cited by 37
Genome-Wide Off-Target Analysis in CRISPR-Cas9 Modified Mice and Their Offspring
Yan, D., Li, H., Zhao, L., Koopman, P. A., Zhang, F., & Huang, J. X. (2019) · G3 Genes Genomes Genetics · doi:10.1534/g3.119.400503 · Cited by 36
Simon, D. A., Tálas, A., Kulcsár, P. I., Biczók, Z., Krausz, S. L., Várady, G., & Welker, E. (2022) · eLife · doi:10.7554/elife.69504 · Cited by 40
An engineered xCas12i with high activity, high specificity and broad PAM range
Zhang, H., Kong, X., Xue, M., Hu, J., Wang, Z., Wei, Y., Wang, H., Zhou, J., Zhang, W., Xu, M., et al. (2022) · Protein & Cell · doi:10.1093/procel/pwac052 · Cited by 60
CRISPR Technologies in Chinese Hamster Ovary Cell Line Engineering
Glinšek, K., Bozovičar, K., & Bratkovič, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098144 · Cited by 42
Metadata
- Authors
- Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- City University of Hong Kong (HK)
- Corresponding author
- Joung, J. Keith
- ORCID
- Venue
- Nature
- Published
- 2016-01-06
- Volume
- 529
- Issue
- 7587
- Pages
- 490-495
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4851738
- OpenAlex
- W2224398381
- Cited by
- 2,673
- References
- 47
- Citations by year
- 2026: 189 · 2025: 221 · 2024: 200 · 2023: 181 · 2022: 267 · 2021: 273 · 2020: 287 · 2019: 284 · 2018: 284 · 2017: 267 · 2016: 215
- FWCI
- 181.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM107427, R01GM088040)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, off-target mutations, Streptococcus pyogenes, single guide RNA, targeted sequencing, genome editing
- MeSH terms
- Base Sequence, DNA, DNA-Binding Proteins, Endonucleases, Genetic Engineering, Humans, Mutation, Protein Binding, RNA, Streptococcus pyogenes, Substrate Specificity, Reproducibility of Results, Genome, Human, Sequence Analysis, DNA, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.